Brainstorm-Cell Therapeutics

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

NurOwn® (MSC-NTF cells) · Neurology
NurOwn delivers mesenchymal stem cells engineered to secrete neurotrophic factors that support motor neuron survival and function in amyotrophic lateral sclerosis (ALS).

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Brainstorm-Cell Therapeutics portfolio CI brief
Brainstorm-Cell Therapeutics pipeline updates RSS

Frequently asked questions about Brainstorm-Cell Therapeutics

What is Brainstorm-Cell Therapeutics's pipeline?

Brainstorm-Cell Therapeutics has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include NurOwn® (MSC-NTF cells).

Sector hub: All tracked pharma companies